AZD6140 + Placebo

Phase 1Completed

0 views this week 0 watching💤 Quiet

Interest: 29/100

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Blood Flow Speed

Conditions

Blood Flow Speed, Coronary Flow Velocity

Trial Timeline

Dec 1, 2010 → Apr 1, 2011

NCT ID

NCT01226602

About AZD6140 + Placebo

AZD6140 + Placebo is a phase 1 stage product being developed by AstraZeneca for Blood Flow Speed. The current trial status is completed. This product is registered under clinical trial identifier NCT01226602. Target conditions include Blood Flow Speed, Coronary Flow Velocity.

What happened to similar drugs?

7 of 17 similar drugs in Blood Flow Speed were approved

Approved (7) Terminated (6) Active (7)

✅micafungin + voriconazoleAstellas PharmaApproved

✅Bunazosin + Doxazosin + ValsartinEisaiApproved

🔄Metoprolol Succinate + HydrochlorothiazideAstraZenecaPhase 3

✅AliskirenNovartisApproved

✅Aliskiren and HCTZNovartisApproved

🔄Beriplex® P/N (Kcentra) + Fresh frozen plasmaCSLPhase 3

🔄Fibrinogen Concentrate (Human) (FCH) + PlaceboCSLPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01226602	Phase 1	Completed	Dec 1, 2010	Apr 1, 2011	Blood Flow Speed

Competing Products

20 competing products in Blood Flow Speed

See all competitors

Product	Company	Stage	Hype Score
micafungin + voriconazole	Astellas Pharma	Approved	35
Cefiderocol	Shionogi	Phase 2	35
Bunazosin + Doxazosin + Valsartin	Eisai	Approved	43
Pegfilgrastim	Kyowa Kirin	Phase 2	35
epoetin alfa	Johnson & Johnson	Phase 2/3	38
epoetin alfa	Johnson & Johnson	Phase 2/3	38
epoetin alfa	Johnson & Johnson	Phase 2	35
Metoprolol Succinate + Hydrochlorothiazide	AstraZeneca	Phase 3	40
NKTR-118 + moxifloxacin + Placebo	AstraZeneca	Phase 1	29
MEDI-551	AstraZeneca	Phase 1	29
Ecallantide + Cyklokapron(R)	Merck	Phase 2	35
Daptomycin	Merck	Phase 2	35
ecallantide + placebo	Merck	Phase 2	35
MK0859	Merck	Phase 1	29
Ecallantide + Placebo	Merck	Phase 2	27
HSC835	Novartis	Phase 2	35
Aliskiren	Novartis	Approved	35
Aliskiren and HCTZ	Novartis	Approved	43
Aliskiren + Amlodipine + Placebo Aliskiren + Placebo Amlodipine	Novartis	Phase 2	35
Darbepoetin alfa	Amgen	Phase 1/2	32